Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Mini-Review Article

Application of Induced Pluripotent Stem Cells in Moyamoya Disease: Progress and Promises

Author(s): Yimeng Xue, Qian Zhang, Lin-Jian Wang, Wen-Jun Tu and Jizong Zhao*

Volume 18, Issue 6, 2023

Published on: 01 September, 2022

Page: [733 - 739] Pages: 7

DOI: 10.2174/1574888X17666220607121027

Price: $65

Abstract

Moyamoya disease (MMD) is a chronic steno-occlusion cerebrovascular disease accompanied by the formation of the abnormal vascular network at the base of the brain. The etiology of MMD is not fully clarified. Lack of pathological specimens hinders the research progress. Induced pluripotent stem cells (iPSC) derived from patients with outstanding differentiation potential and infinite proliferation ability could conquer the problem of insufficient samples. The technology of iPSC holds the promise of clarifying the underlying molecular mechanism in the development of MMD. In this review, we summarized the latest progress and difficulties in the research of mechanism and detailed the application of iPSC in MMD, aiming to provide an outlook of iPSC in molecular mechanism and novel therapies of MMD.

Keywords: Induced pluripotent stem cell, moyamoya disease, ring finger protein 213, cerebral vascular disease, endothelial cell, vascular smooth muscle cell.

Graphical Abstract
[1]
Suzuki J, Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969; 20(3): 288-99.
[http://dx.doi.org/10.1001/archneur.1969.00480090076012] [PMID: 5775283]
[2]
Acker G, Fekonja L, Vajkoczy P. Surgical management of moyamoya disease. Stroke 2018; 49(2): 476-82.
[http://dx.doi.org/10.1161/STROKEAHA.117.018563] [PMID: 29343587]
[3]
Bersano A, Guey S, Bedini G, et al. European moyamoya disease initiative. Research progresses in understanding the pathophysiology of moyamoya disease. Cerebrovasc Dis 2016; 41(3-4): 105-18.
[http://dx.doi.org/10.1159/000442298] [PMID: 26756907]
[4]
Wang Y, Yin P, Bian GL, et al. The combination of stem cells and tissue engineering: An advanced strategy for blood vessels regeneration and vascular disease treatment. Stem Cell Res Ther 2017; 8(1): 194.
[http://dx.doi.org/10.1186/s13287-017-0642-y] [PMID: 28915929]
[5]
Lim RG, Quan C, Reyes-Ortiz AM, et al. Huntington’s disease iPSC-derived brain microvascular endothelial cells reveal WNT-mediated angiogenic and blood-brain barrier deficits. Cell Rep 2017; 19(7): 1365-77.
[http://dx.doi.org/10.1016/j.celrep.2017.04.021] [PMID: 28514657]
[6]
Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 2008; 79(8): 900-4.
[http://dx.doi.org/10.1136/jnnp.2007.130666] [PMID: 18077479]
[7]
Ahn IM, Park DH, Hann HJ, Kim KH, Kim HJ, Ahn HS. Incidence, prevalence, and survival of moyamoya disease in Korea: A nationwide, population-based study. Stroke 2014; 45(4): 1090-5.
[http://dx.doi.org/10.1161/STROKEAHA.113.004273] [PMID: 24595588]
[8]
Miao W, Zhao PL, Zhang YS, et al. Epidemiological and clinical features of Moyamoya disease in Nanjing, China. Clin Neurol Neurosurg 2010; 112(3): 199-203.
[http://dx.doi.org/10.1016/j.clineuro.2009.11.009] [PMID: 20004511]
[9]
Kainth D, Chaudhry SA, Kainth H, Suri FK, Qureshi AI. Epidemiological and clinical features of moyamoya disease in the USA. Neuroepidemiology 2013; 40(4): 282-7.
[http://dx.doi.org/10.1159/000345957] [PMID: 23445954]
[10]
Fukui M, Kono S, Sueishi K, Ikezaki K. Moyamoya disease 2000; 20(s1): 61-4.
[http://dx.doi.org/10.1046/j.1440-1789.2000.00300.x]
[11]
Takekawa Y, Umezawa T, Ueno Y, Sawada T, Kobayashi M. Pathological and immunohistochemical findings of an autopsy case of adult moyamoya disease. Neuropathology. Official J Japanese Society Neuropathol 2004; 24(3): 236-42.
[12]
Matsuo M, Nadanaka S, Soga M, et al. Vulnerability to shear stress caused by altered peri-endothelial matrix is a key feature of Moyamoya disease. Sci Rep 2021; 11(1): 1552.
[http://dx.doi.org/10.1038/s41598-021-81282-9] [PMID: 33452387]
[13]
Bower RS, Mallory GW, Nwojo M, Kudva YC, Flemming KD, Meyer FB. Moyamoya disease in a primarily white, midwestern US population: Increased prevalence of autoimmune disease. Stroke 2013; 44(7): 1997-9.
[http://dx.doi.org/10.1161/STROKEAHA.111.000307] [PMID: 23652271]
[14]
Wang X, Han C, Jia Y, Wang J, Ge W, Duan L. Proteomic profiling of exosomes from hemorrhagic moyamoya disease and dysfunction of mitochondria in endothelial cells. Stroke 2021; STROKEAHA120032297.
[15]
Li L, Liu P, Wang R, et al. Pathophysiological significance of neutrophilic transfer RNA-derived small RNAs in asymptomatic moyamoya disease. Cells 2021; 10(5): 1086.
[http://dx.doi.org/10.3390/cells10051086] [PMID: 34062929]
[16]
Guo DC, Papke CL, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 2009; 84(5): 617-27.
[http://dx.doi.org/10.1016/j.ajhg.2009.04.007] [PMID: 19409525]
[17]
Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T. Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 1999; 64(2): 533-7.
[http://dx.doi.org/10.1086/302243] [PMID: 9973290]
[18]
Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 2000; 15(3): 179-82.
[http://dx.doi.org/10.1177/088307380001500307] [PMID: 10757474]
[19]
Sakurai K, Horiuchi Y, Ikeda H, et al. A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 2004; 49(5): 278-81.
[http://dx.doi.org/10.1007/s10038-004-0143-6] [PMID: 15362573]
[20]
Yamauchi T, Tada M, Houkin K, et al. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 2000; 31(4): 930-5.
[http://dx.doi.org/10.1161/01.STR.31.4.930] [PMID: 10754001]
[21]
Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 2011; 6(7): e22542.
[http://dx.doi.org/10.1371/journal.pone.0022542] [PMID: 21799892]
[22]
Narducci A, Yasuyuki K, Onken J, Blecharz K, Vajkoczy P. In vivo demonstration of blood-brain barrier impairment in Moyamoya disease. Acta Neurochir (Wien) 2019; 161(2): 371-8.
[http://dx.doi.org/10.1007/s00701-019-03811-w] [PMID: 30675657]
[23]
Kundishora AJ, Peters ST, Pinard A, et al. DIAPH1 variants in non-east asian patients with sporadic moyamoya disease. JAMA Neurol 2021; 78(8): 993-1003.
[http://dx.doi.org/10.1001/jamaneurol.2021.1681] [PMID: 34125151]
[24]
Miyatake S, Miyake N, Touho H, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology 2012; 78(11): 803-10.
[http://dx.doi.org/10.1212/WNL.0b013e318249f71f] [PMID: 22377813]
[25]
Cecchi AC, Guo D, Ren Z, et al. RNF213 rare variants in an ethnically diverse population with Moyamoya disease. Stroke 2014; 45(11): 3200-7.
[http://dx.doi.org/10.1161/STROKEAHA.114.006244] [PMID: 25278557]
[26]
Wen J, Sun X, Chen H, et al. Mutation of rnf213a by TALEN causes abnormal angiogenesis and circulation defects in zebrafish. Brain Res 2016; 1644: 70-8.
[http://dx.doi.org/10.1016/j.brainres.2016.04.051] [PMID: 27125596]
[27]
Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 2002; 248(2): 307-18.
[http://dx.doi.org/10.1006/dbio.2002.0711] [PMID: 12167406]
[28]
Kobayashi H, Yamazaki S, Takashima S, et al. Ablation of Rnf213 retards progression of diabetes in the Akita mouse. Biochem Biophys Res Commun 2013; 432(3): 519-25.
[http://dx.doi.org/10.1016/j.bbrc.2013.02.015] [PMID: 23410753]
[29]
Sonobe S, Fujimura M, Niizuma K, et al. Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213: A susceptibility gene for moyamoya disease. Brain Res 2014; 1552: 64-71.
[http://dx.doi.org/10.1016/j.brainres.2014.01.011] [PMID: 24440776]
[30]
Kobayashi H, Matsuda Y, Hitomi T, et al. Biochemical and functional characterization of RNF213 (Mysterin) R4810K, a susceptibility mutation of moyamoya disease, in angiogenesis in vitro and in vivo. J Am Heart Assoc 2015; 4(7): e002146.
[http://dx.doi.org/10.1161/JAHA.115.002146] [PMID: 26126547]
[31]
Sato-Maeda M, Fujimura M, Kanoke A, Morita-Fujimura Y, Niizuma K, Tominaga T. Transient middle cerebral artery occlusion in mice induces neuronal expression of RNF213, a susceptibility gene for moyamoya disease. Brain Res 2016; 1630: 50-5.
[http://dx.doi.org/10.1016/j.brainres.2015.10.055] [PMID: 26556774]
[32]
Sonobe S, Fujimura M, Niizuma K, et al. Increased vascular MMP-9 in mice lacking RNF213: Moyamoya disease susceptibility gene. Neuroreport 2014; 25(18): 1442-6.
[http://dx.doi.org/10.1097/WNR.0000000000000289] [PMID: 25383461]
[33]
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-72.
[http://dx.doi.org/10.1016/j.cell.2007.11.019] [PMID: 18035408]
[34]
Merkle FT, Eggan K. Modeling human disease with pluripotent stem cells: From genome association to function. Cell Stem Cell 2013; 12(6): 656-68.
[http://dx.doi.org/10.1016/j.stem.2013.05.016] [PMID: 23746975]
[35]
Jang S, Collin de l’Hortet A, Soto-Gutierrez A. Induced pluripotent stem cell-derived endothelial cells: Overview, current advances, applications, and future directions. Am J Pathol 2019; 189(3): 502-12.
[http://dx.doi.org/10.1016/j.ajpath.2018.12.004] [PMID: 30653953]
[36]
Hitomi T, Habu T, Kobayashi H, et al. Downregulation of Securin by the variant RNF213 R4810K (rs112735431, G>A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients. Biochem Biophys Res Commun 2013; 438(1): 13-9.
[http://dx.doi.org/10.1016/j.bbrc.2013.07.004] [PMID: 23850618]
[37]
Hitomi T, Habu T, Kobayashi H, et al. The moyamoya disease susceptibility variant RNF213 R4810K (rs112735431) induces genomic instability by mitotic abnormality. Biochem Biophys Res Commun 2013; 439(4): 419-26.
[http://dx.doi.org/10.1016/j.bbrc.2013.08.067] [PMID: 23994138]
[38]
Cardano M, Marsoner F, Marcatili M, et al. Establishment of induced pluripotent stem cell (iPSC) line from 55-year old male patient with hemorrhagic Moyamoya disease. Stem Cell Res (Amst) 2016; 17(3): 623-6.
[http://dx.doi.org/10.1016/j.scr.2016.11.006] [PMID: 27934594]
[39]
Cardano M, Marsoner F, Zasso J, et al. Establishment of induced pluripotent stem cell (iPSC) line from an 8-year old female patient with ischemic Moyamoya disease. Stem Cell Res (Amst) 2016; 17(3): 619-22.
[http://dx.doi.org/10.1016/j.scr.2016.11.007] [PMID: 27934593]
[40]
Hamauchi S, Shichinohe H, Uchino H, et al. Cellular functions and gene and protein expression profiles in endothelial cells derived from moyamoya disease-specific iPS cells. PLoS One 2016; 11(9): e0163561.
[http://dx.doi.org/10.1371/journal.pone.0163561] [PMID: 27662211]
[41]
Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet 2019; 20(7): 377-88.
[http://dx.doi.org/10.1038/s41576-019-0100-z] [PMID: 30737492]
[42]
Uchino H, Ito M, Kazumata K, et al. Circulating miRNome profiling in Moyamoya disease-discordant monozygotic twins and endothelial microRNA expression analysis using iPS cell line. BMC Med Genomics 2018; 11(1): 72.
[http://dx.doi.org/10.1186/s12920-018-0385-3] [PMID: 30157848]
[43]
Masuda J, Ogata J, Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke 1993; 24(12): 1960-7.
[http://dx.doi.org/10.1161/01.STR.24.12.1960] [PMID: 7902623]
[44]
Lin R, Xie Z, Zhang J, et al. Clinical and immunopathological features of moyamoya disease. PLoS One 2012; 7(4): e36386.
[http://dx.doi.org/10.1371/journal.pone.0036386] [PMID: 22558457]
[45]
Kang HS, Moon YJ, Kim YY, et al. Smooth-muscle progenitor cells isolated from patients with moyamoya disease: Novel experimental cell model. J Neurosurg 2014; 120(2): 415-25.
[http://dx.doi.org/10.3171/2013.9.JNS131000] [PMID: 24160477]
[46]
Tokairin K, Hamauchi S, Ito M, et al. Vascular smooth muscle cell derived from IPS cell of moyamoya disease-comparative characterization with endothelial cell transcriptome. J Stroke Cerebrovas Dis: The official journal of National Stroke Association 2020; 29(12): 105305.
[47]
Milliat F, François A, Isoir M, et al. Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: Implication in radiation-induced vascular damages. Am J Pathol 2006; 169(4): 1484-95.
[http://dx.doi.org/10.2353/ajpath.2006.060116] [PMID: 17003501]
[48]
Cheung C, Bernardo AS, Trotter MW, Pedersen RA, Sinha S. Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility. Nat Biotechnol 2012; 30(2): 165-73.
[http://dx.doi.org/10.1038/nbt.2107] [PMID: 22252507]
[49]
Korn J, Christ B, Kurz H. Neuroectodermal origin of brain pericytes and vascular smooth muscle cells. J Comp Neurol 2002; 442(1): 78-88.
[http://dx.doi.org/10.1002/cne.1423] [PMID: 11754368]
[50]
Etchevers HC, Vincent C, Le Douarin NM, Couly GF. The cephalic neural crest provides pericytes and smooth muscle cells to all blood vessels of the face and forebrain. Development 2001; 128(7): 1059-68.
[http://dx.doi.org/10.1242/dev.128.7.1059] [PMID: 11245571]
[51]
Ehler E, Karlhuber G, Bauer HC, Draeger A. Heterogeneity of smooth muscle-associated proteins in mammalian brain microvasculature. Cell Tissue Res 1995; 279(2): 393-403.
[http://dx.doi.org/10.1007/BF00318497] [PMID: 7895277]
[52]
Kotani Y, Morito D, Yamazaki S, et al. Neuromuscular regulation in zebrafish by a large AAA+ ATPase/ubiquitin ligase, mysterin/RNF213. Sci Rep 2015; 5(1): 16161.
[http://dx.doi.org/10.1038/srep16161] [PMID: 26530008]
[53]
Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110(9): 3507-12.
[http://dx.doi.org/10.1073/pnas.1222878110] [PMID: 23401516]
[54]
Blecharz KG, Frey D, Schenkel T, et al. Autocrine release of angiopoietin-2 mediates cerebrovascular disintegration in Moyamoya disease. J Cereb Blood Flow Metab 2017; 37(4): 1527-39.
[http://dx.doi.org/10.1177/0271678X16658301] [PMID: 27381827]
[55]
Rafat N, Beck GCh, Peña-Tapia PG, Schmiedek P, Vajkoczy P. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke 2009; 40(2): 432-8.
[http://dx.doi.org/10.1161/STROKEAHA.108.529420] [PMID: 19095988]
[56]
Kaku Y, Morioka M, Ohmori Y, et al. Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image: Is arterial constrictive remodeling a major pathogenesis? Acta Neurochir (Wien) 2012; 154(12): 2151-7.
[http://dx.doi.org/10.1007/s00701-012-1472-4] [PMID: 22935819]
[57]
Hopkins AM, DeSimone E, Chwalek K, Kaplan DL. 3D in vitro modeling of the central nervous system. Prog Neurobiol 2015; 125: 1-25.
[http://dx.doi.org/10.1016/j.pneurobio.2014.11.003] [PMID: 25461688]
[58]
Psaltis PJ, Simari RD. Vascular wall progenitor cells in health and disease. Circ Res 2015; 116(8): 1392-412.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.305368] [PMID: 25858065]
[59]
Wimmer RA, Leopoldi A, Aichinger M, Kerjaschki D, Penninger JM. Generation of blood vessel organoids from human pluripotent stem cells. Nat Protoc 2019; 14(11): 3082-100.
[http://dx.doi.org/10.1038/s41596-019-0213-z] [PMID: 31554955]
[60]
Lancaster MA, Renner M, Martin CA, et al. Cerebral organoids model human brain development and microcephaly. Nature 2013; 501(7467): 373-9.
[http://dx.doi.org/10.1038/nature12517] [PMID: 23995685]
[61]
Mansour AA, Gonçalves JT, Bloyd CW, et al. An in vivo model of functional and vascularized human brain organoids. Nat Biotechnol 2018; 36(5): 432-41.
[http://dx.doi.org/10.1038/nbt.4127] [PMID: 29658944]
[62]
Cakir B, Xiang Y, Tanaka Y, et al. Engineering of human brain organoids with a functional vascular-like system. Nat Methods 2019; 16(11): 1169-75.
[http://dx.doi.org/10.1038/s41592-019-0586-5] [PMID: 31591580]
[63]
Pham MT, Pollock KM, Rose MD, et al. Generation of human vascularized brain organoids. Neuroreport 2018; 29(7): 588-93.
[http://dx.doi.org/10.1097/WNR.0000000000001014] [PMID: 29570159]
[64]
Wörsdörfer P, Dalda N, Kern A, et al. Generation of complex human organoid models including vascular networks by incorporation of mesodermal progenitor cells. Sci Rep 2019; 9(1): 15663.
[http://dx.doi.org/10.1038/s41598-019-52204-7] [PMID: 31666641]
[65]
Kim Y I, Phi J H, Paeng J C, et al. In vivo evaluation of angiogenic activity and its correlation with efficacy of indirect revascularization surgery in pediatric moyamoya disease. J Nuc Medi: Official publication, Society of Nuclear Medicine 2014; 55(9): 1467-72.
[66]
Kim T, Oh CW, Bang JS, Kim JE, Cho WS. Moyamoya Disease: Treatment and Outcomes. J Stroke 2016; 18(1): 21-30.
[http://dx.doi.org/10.5853/jos.2015.01739] [PMID: 26846757]
[67]
Jeon C, Yeon JY, Jo KI, Hong SC, Kim JS. Clinical role of microembolic signals in adult moyamoya disease with ischemic stroke. Stroke 2019; 50(5): 1130-5.
[http://dx.doi.org/10.1161/STROKEAHA.118.022490] [PMID: 30935317]
[68]
Bang OY, Fujimura M, Kim SK. The Pathophysiology of Moyamoya Disease: An Update. J Stroke 2016; 18(1): 12-20.
[http://dx.doi.org/10.5853/jos.2015.01760] [PMID: 26846756]
[69]
Vatine G, Barrile R, Workman M, et al. Human iPSC-derived blood-brain barrier chips enable disease modeling and personalized medicine applications. Cell Stem Cell 2019; 24(6): 995-1005.
[http://dx.doi.org/10.1016/j.stem.2019.05.011]
[70]
Dash BC, Setia O, Gorecka J, et al. A dense fibrillar collagen scaffold differentially modulates secretory function of iPSC-derived vascular smooth muscle cells to promote wound healing. Cells 2020; 9(4): E966.
[http://dx.doi.org/10.3390/cells9040966] [PMID: 32295218]
[71]
Luo J, Qin L, Kural MH, et al. Vascular smooth muscle cells derived from inbred swine induced pluripotent stem cells for vascular tissue engineering. Biomaterials 2017; 147: 116-32.
[http://dx.doi.org/10.1016/j.biomaterials.2017.09.019] [PMID: 28942128]
[72]
Weber B, Kehl D, Bleul U, et al. In vitro fabrication of autologous living tissue-engineered vascular grafts based on prenatally harvested ovine amniotic fluid-derived stem cells. J Tissue Eng Regen Med 2016; 10(1): 52-70.
[http://dx.doi.org/10.1002/term.1781] [PMID: 23881794]
[73]
Wang L, Hu J, Sorek CE, Chen EY, Ma PX, Yang B. Fabrication of tissue-engineered vascular grafts with stem cells and stem cell-derived vascular cells. Expert Opin Biol Ther 2016; 16(3): 317-30.
[http://dx.doi.org/10.1517/14712598.2016.1118460] [PMID: 26560995]
[74]
Hara S, Hori M, Murata S, et al. Microstructural damage in normal-appearing brain parenchyma and neurocognitive dysfunction in adult moyamoya disease. Stroke 2018; 49(10): 2504-7.
[http://dx.doi.org/10.1161/STROKEAHA.118.022367] [PMID: 30355113]
[75]
Festa JR, Schwarz LR, Pliskin N, et al. Neurocognitive dysfunction in adult moyamoya disease. J Neurol 2010; 257(5): 806-15.
[http://dx.doi.org/10.1007/s00415-009-5424-8] [PMID: 20033200]
[76]
Zhao L, Sun W, Liang H, et al. Therapeutic effect of autologous bone marrow stem cell mobilization combined with anti-infective therapy on moyamoya disease. Saudi J Biol Sci 2020; 27(2): 676-81.
[http://dx.doi.org/10.1016/j.sjbs.2019.12.016] [PMID: 32210687]
[77]
Bressan E, Ferroni L, Gardin C, et al. Metal nanoparticles released from dental implant surfaces: Potential contribution to chronic inflammation and peri-implant bone loss. Materials 2019; 12(12): 2036.
[78]
D’Onofrio N, Balestrieri A, Neglia G, et al. chemistry, f., Antioxidant and Anti-Inflammatory Activities of Buffalo Milk δ-Valerobetaine. J Agric Food Chem 2019; 67(6): 1702-10.

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy